These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 15776868)
1. [Cytotoxic T lymphocytes in cancer and autoimmunity]. Prado-García H; Avila-Moreno F; López-González JS Rev Invest Clin; 2004; 56(5):629-39. PubMed ID: 15776868 [TBL] [Abstract][Full Text] [Related]
2. Tumor resistance to CD8+ T cell-based therapeutic vaccination. Huang Y; Shah S; Qiao L Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376 [TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocytes: all roads lead to death. Barry M; Bleackley RC Nat Rev Immunol; 2002 Jun; 2(6):401-9. PubMed ID: 12093006 [TBL] [Abstract][Full Text] [Related]
4. Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer. Ramanathan S; Gagnon J; Ilangumaran S Arch Immunol Ther Exp (Warsz); 2008; 56(5):311-23. PubMed ID: 18836862 [TBL] [Abstract][Full Text] [Related]
5. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity. Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732 [TBL] [Abstract][Full Text] [Related]
6. [Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with autologous cervical cancer antigen]. Zhou CJ; Ma W; Zhou JD; Zhao YX; Xie HQ Ai Zheng; 2006 Feb; 25(2):143-7. PubMed ID: 16480575 [TBL] [Abstract][Full Text] [Related]
7. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. Khadra A; Santamaria P; Edelstein-Keshet L J Theor Biol; 2009 Jan; 256(1):126-41. PubMed ID: 18950644 [TBL] [Abstract][Full Text] [Related]
8. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268 [TBL] [Abstract][Full Text] [Related]
9. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors. Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015 [TBL] [Abstract][Full Text] [Related]
10. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. Rolle CE; Carrio R; Malek TR Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768 [TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732 [TBL] [Abstract][Full Text] [Related]
12. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing. Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 increases proliferation and interferon-gamma production but not cytolytic activity of human antigen-specific effector memory cytotoxic T lymphocytes: power of the effect depends on the functional avidity of the T cell and the antigen concentration. Bontkes HJ; Ruizendaal JJ; Kramer D; Meijer CJ; Schreurs MW; Hooijberg E Hum Immunol; 2005 Nov; 66(11):1137-45. PubMed ID: 16571414 [TBL] [Abstract][Full Text] [Related]
14. Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Jabri B; Ebert E Immunol Rev; 2007 Feb; 215():202-14. PubMed ID: 17291290 [TBL] [Abstract][Full Text] [Related]
15. Differential susceptibility of leukocyte subsets to cytotoxic T cell killing: implications for HIV immunopathogenesis. Liu J; Roederer M Cytometry A; 2007 Feb; 71(2):94-104. PubMed ID: 17200952 [TBL] [Abstract][Full Text] [Related]
16. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. Boissonnas A; Fetler L; Zeelenberg IS; Hugues S; Amigorena S J Exp Med; 2007 Feb; 204(2):345-56. PubMed ID: 17261634 [TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837 [TBL] [Abstract][Full Text] [Related]
18. The 'kiss of death' by dendritic cells to cancer cells. Chan CW; Housseau F Cell Death Differ; 2008 Jan; 15(1):58-69. PubMed ID: 17948029 [TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353 [TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment and immune escape. Ferrone S; Whiteside TL Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]